United States Patent 6,682,348: A Detailed Analysis
Introduction
United States Patent 6,682,348, titled "Dispensing apparatus and cartridge," is a significant patent in the field of dental care, particularly for the treatment of periodontal disease. This patent, owned by Orapharma Inc., is associated with the drug Arestin, which uses Minocycline Hydrochloride as its active ingredient.
Patent Overview
The patent US6682348 was issued on January 27, 2004, and it has since expired, with its last expiry date being March 2022[1][2].
Claims and Description
The patent describes a device designed for the treatment of periodontal disease. Here are the key aspects of the device:
Handle and Cartridge Design
The device includes a handle that has a configuration familiar to dental professionals, making it easier to use and maneuver. The handle is designed to accommodate a cartridge, which contains the medication[2][5].
Cartridge Details
The cartridge is detachable and contains the extended-release formulation of Minocycline Hydrochloride. This design allows for precise and controlled delivery of the medication directly into the periodontal pocket, which is crucial for treating periodontal disease effectively[2][5].
Dispensing Mechanism
The patent details a dispensing mechanism that ensures the medication is delivered in a consistent and controlled manner. This mechanism is integral to the effectiveness of the treatment, as it ensures that the correct dosage is administered each time[2].
Patent Expiry and Generic Launch
The patent US6682348 has expired as of March 2022. This expiry has paved the way for the launch of generic versions of Arestin. Multiple companies, including Aurobindo Pharma Ltd, have filed and received approval for generic versions of Minocycline Hydrochloride, the active ingredient in Arestin[1].
Legal Activities and Patent Landscape
The patent's lifecycle involved several legal activities, including the payment of maintenance fees and issue notifications. These activities are crucial in understanding the patent's status and any potential extensions or amendments that could affect its expiry date[1].
International Patent Protection
While the patent US6682348 provides insights into exclusivity within the United States, Arestin is protected by patents in multiple countries. Understanding the broader patent landscape is essential for strategizing market entry and identifying markets with weaker patent protection[1].
Competitive Landscape
Arestin faces competition from other brand drugs and generics that use the same active ingredient, Minocycline Hydrochloride. Knowing the competitors and their market strategies is vital for planning effective market entry and growth[1].
Impact on Dental Care
The device and cartridge system described in the patent have significantly impacted the treatment of periodontal disease. The precise delivery of medication directly into the periodontal pocket has improved treatment outcomes and patient care.
Innovation in Dental Technology
The expiration of this patent and the subsequent generic launches do not diminish the innovative spirit behind the original device. Instead, they open up opportunities for further innovation and improvement in dental care technology.
AI and Data Analysis in Dental Care
Recent advancements in dental AI, such as those by Pearl, highlight the evolving landscape of dental care. Patents like the one granted to Pearl for "Computer Vision-Based Analysis Of Provider Data" demonstrate how AI and data analysis are transforming dental practices by identifying missed treatment opportunities and improving clinical performance[4].
Conclusion
The United States Patent 6,682,348 has played a significant role in the treatment of periodontal disease through its innovative dispensing apparatus and cartridge design. With its expiry, the market has opened up for generic versions, enhancing accessibility and competition. As dental care technology continues to evolve, patents like these remain crucial in driving innovation and improving patient outcomes.
Key Takeaways
- Patent Expiry: The patent US6682348 expired in March 2022, allowing for generic launches.
- Device Design: The patent describes a handle and cartridge system for precise medication delivery.
- Generic Competition: Multiple companies have filed for generic versions of Arestin.
- International Protection: Arestin is protected by patents in multiple countries.
- Innovation: The patent's expiry opens up opportunities for further innovation in dental care technology.
Frequently Asked Questions
Q: What is the active ingredient in Arestin?
A: The active ingredient in Arestin is Minocycline Hydrochloride.
Q: When did the patent US6682348 expire?
A: The patent US6682348 expired in March 2022.
Q: What companies have filed for generic versions of Arestin?
A: Multiple companies, including Aurobindo Pharma Ltd, have filed for generic versions of Arestin.
Q: How does the device described in the patent work?
A: The device includes a handle and a detachable cartridge that contains the extended-release formulation of Minocycline Hydrochloride, designed for precise delivery into the periodontal pocket.
Q: What is the significance of AI in dental care as related to this patent?
A: While AI is not directly related to this patent, recent advancements in dental AI, such as those by Pearl, highlight the evolving landscape of dental care and the potential for future innovations.
Cited Sources
- Pharsight, Arestin patent expiration - Pharsight.
- Unified Patents Portal, US-6682348-B2 - Unified Patents Portal.
- Touro Law Review, Mastering Patent Claim Construction.
- HelloPearl, Pearl Granted U.S. Patent for Dental Practice Data Analysis AI Technology.
- Google Patents, US20210338401A1 - Device, method, and system ... - Google Patents.
